BRD4 and neuroblastoma: To investigate whether RBM39 itself is a MYC target, we assessed the epigenetic landscape of RBM39 genomic locus in a primary neuroblastoma with MYCN amplification, which showed MYCN binding at the promoter region of RBM39, in line with the binding of BRD4, CTCF, RNA polymerase II, and enrichment of active transcriptional marks (H3K27Ac, H3K9-14Ac, H3K4me3, H3K4me2, H3K4me1, and H3K36me3) (fig.